TELO_OUT_1 [2025-04-02 14:48:15 -0400] 2773 Bytes | 709 tokens | Cum: 709 tkns (8.86% of 8k)
==========================================================================

We're scouting for winners today. Its 2:48:14 PM on Wed Apr 02, 2025 -0400 and I'm looking at Telomir Pharmaceuticals (TELO) up to 3.16 from 2.74

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Telomir Pharmaceuticals (TELO)
IPO: IPO date unknown
Shares Outstanding: 29,760,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS

Here's the first list of news for Telomir Pharmaceuticals:

C1 - Mar-19-25 08:00AM - Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
C2 - Feb-26-25 08:00AM - Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
C3 - Feb-21-25 08:00AM - Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
C4 - Feb-20-25 04:01PM - Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration
C5 - Feb-18-25 08:00AM - Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
C6 - Jan-28-25 08:00AM - Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses
C7 - Jan-07-25 08:00AM - Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
C8 - Dec-23-24 07:30AM - Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Telomir Pharmaceuticals (TELO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

TELO_OUT_3 [2025-04-02 14:48:16 -0400] 1099 Bytes | 264 tokens | Cum: 975 tkns (12.19% of 8k)
==========================================================================

Showing C2 (chunk 1 of 14): C2:
**Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines**
Date: Feb-26-25 08:00AM
Source: (ACCESSWIRE)
URL: https://www.accesswire.com/viewarticle.aspx?id=991455

The first and only All-in-one subscription platform offering
all of your PR Distribution and Media Outreach Tools in one
single solution.Monthly & Annual Subscriptions.

Find & create journalist lists with the most up to date database in the industry.

Personalize and customize your pitch for maximum engagement.

Discover your brand, industry, and competitor mentions.

The first and only All-in-one subscription platform that offers you the ability
to manage all of your IR communications needs from a single
source.Explore our IR subscriptions

Ensure your IR Site is accessible for your entire audience.

Experience s

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TELO_OUT_5 [2025-04-02 14:48:17 -0400] 1039 Bytes | 279 tokens | Cum: 1256 tkns (15.70% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-19T13:00:00Z - Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Us...
A2 - 2025-03-19T12:06:43Z - Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Us...
A3 - 2025-03-19T12:09:24Z - Telomir Pharmaceuticals (TELO) Announces Significant Anti-Cancer Effects in Prostate Cancer Animal M...
A4 - 2025-03-19T11:37:03Z - Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cell...
A5 - 2025-03-19T11:42:12Z - Telomir Pharmaceuticals (TELO) Announces Significant Anti-Cancer Effects in Prostate Cancer Animal M...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TELO_OUT_7 [2025-04-02 14:48:21 -0400] 1098 Bytes | 294 tokens | Cum: 1552 tkns (19.40% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells**Date: 2025-03-19Source: {'uri': 'wallstreet-online.de', 'dataType': 'news', 'title': 'wallstreet:online'}URL: https://www.wallstreet-online.de/nachricht/19130755-telomir-pharmaceuticals-announces-significant-anti-cancer-effects-prostate-cancer-animal-model-using-highly-aggressive-human-prostate-cancer-cellsTelomir-1 Inhibits Tumor Growth, Suppresses Cancer Progression, and Neutralizes Chemotherapy Toxicity

MIAMI, FLORIDA / ACCESS Newswire / March 19, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today announced groundbreaking preclinical findings demonstrating that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model using highly aggressive human pros

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TELO_OUT_9 [2025-04-02 14:48:26 -0400] 549 Bytes | 133 tokens | Cum: 1766 tkns (22.07% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): tate cancer cells. It was found that Telomir-1 actively suppresses cancer growth rather than promoting it, and protects against chemotherapy-induced toxicity and mortality when combined with Paclitaxel-a widely used chemotherapy drug known for its effectiveness in treating various cancers but often associated with severe toxicity and side effects.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TELO_OUT_11 [2025-04-02 14:48:27 -0400] 1218 Bytes | 356 tokens | Cum: 2248 tkns (28.10% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-07-02T12:30:00Z - Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes
B2 - 2024-06-17T20:10:00Z - Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel
B3 - 2024-05-30T12:30:00Z - Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
B4 - 2024-04-16T12:30:00Z - Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
B5 - 2024-04-02T12:30:00Z - Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
B6 - 2024-03-29T20:44:00Z - UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TELO_OUT_13 [2025-04-02 14:48:30 -0400] 1075 Bytes | 301 tokens | Cum: 2551 tkns (31.89% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/07/02/2907399/0/en/Telomir-Pharmaceuticals-Added-to-Membership-of-Russell-3000-and-Russell-Microcap-Indexes.htmlTAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps as a potential treatment for age-related conditions, today announced that the Company has been added as a member of the broad-market Russell 3000® and the Russell Microcap® Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TELO_OUT_15 [2025-04-02 14:48:31 -0400] 506 Bytes | 121 tokens | Cum: 2764 tkns (34.55% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-04 10-K Item 7.

MGT DISC & ANALYSIS OF

FIN COND & RESULTS OF OPER

The following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of our results of operations and financial co...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TELO_OUT_17 [2025-04-02 14:48:32 -0400] 1098 Bytes | 221 tokens | Cum: 2987 tkns (37.34% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7.

MANAGEMENTS DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of our results of operations and financial condition. You should read the following discussion and analysis of our results of operations and financial condition together with our financial statements and related notes and other information included elsewhere in this Annual Report.

In addition to historical financial information, this discussion contains forward-looking statements based upon our current expectations that involve risks and uncertainties. Our actual results could differ materially from such forward-looking statements as a result of various factors, including those set forth under Risk Factors and Cautionary Note Regarding Forward-Looking

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TELO_OUT_19 [2025-04-02 14:48:37 -0400] 1098 Bytes | 265 tokens | Cum: 3254 tkns (40.67% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): Statements included elsewhere in this Annual Report. Additionally, our historical results are not necessarily indicative of the results that may be expected for any period in the future.

Overview

We are a pre-clinical-stage pharmaceutical company seeking to lead development in age-reversal science. The Company is focused on the development of Telomir-1, a novel small molecule metal ion regulator, designed to lengthen the DNAs protective telomere caps, which are crucial in the aging process. The Companys goal is to explore the potential of Telomir-1 starting with ongoing research in animals and then in humans.

We had net losses of $16.5 million and $13.1 million for the years ended December 31, 2024 and 2023, respectively.

Reverse Stock Split

Effective December 11, 2023, we completed a reverse stock split of our outstanding common stock upon the filing of our Second Amended and

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TELO_OUT_21 [2025-04-02 14:48:46 -0400] 4029 Bytes | 1143 tokens | Cum: 4543 tkns (56.79% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+---------------------+
| Volume: 430,660 | Perf Month: -22.72% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+---------------------+
| Avg Volume: 144.06K | Perf Quarter: -32.54% | Short Float: 11.31% | ROE: -813.12% |
+---------------------+-----------------------+------------------------+---------------------+
| Rel Volume: 3.81 | Index: RUT | Short Ratio: 13.54 | ROI: -2580.37% |
+---------------------+-----------------------+------------------------+---------------------+
| RSI (14): 36.43 | Market Cap: 93.16M | Short Interest: 1.95M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+---------------------+
| ATR (14): 0.48 | Shs Outstand: 29.76M | Beta: 0.03 | EPS Surprise: 0.00% |
+---------------------+-----------------------+------------------------+---------------------+
| SMA20: -24.71% | Shs Float: 17.25M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+---------------------+
| SMA50: -26.86% | Inst Own: 11.98% | Sales past 5Y: 0.00% | Earnings: Feb 26 |
+---------------------+-----------------------+------------------------+---------------------+
| SMA200: -32.75% | Insider Own: 42.03% | Employees: 5 | |
+---------------------+-----------------------+------------------------+---------------------+
| Perf Week: -24.03% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+------------------------+---------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -5990733.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.12
Average Volume: 202935.48
30-Day High: 5.03
30-Day Low: 2.74

[Detailed Financials: Q3 2024]
- Total Assets: $1,041,985.0
- Total Liabilities: $599,911
- Total Equity: $442,074
- Current Assets: $1,041,985.0
- Current Liabilities: $599,911

[Income Statement: Q3 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.2

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0

[Detailed Financials: Q2 2024]
- Total Assets: $2,101,722.0
- Total Liabilities: $534,155
- Total Equity: $1,627,567.0
- Current Assets: $2,101,722.0
- Current Liabilities: $534,155

[Income Statement: Q2 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.05

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

TELO_OUT_23 [2025-04-02 14:48:49 -0400] 676 Bytes | 167 tokens | Cum: 4942 tkns (61.78% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

TELO_IN_25 [2025-04-02 14:48:49 -0400] 126 Bytes | 29 tokens | Cum: 5038 tkns (62.98% of 8k)
==========================================================================

====================================
[2025-04-02 14:48:49] # Analysis Completed
Elapsed Time: 34.88 seconds